Search
Tony Keating says the company will now submit for FDA approval. Photo: Attila Csaszar

ResApp tumbles on study

Shares in medical tech firm ResApp Health have more than halved today, after the company released the preliminary results of a new US study on its technology.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 30/11/18

1 year TSR5 year TSR
69thResApp Health57%73%
161stPeppermint Innovation21%-17%
544thDimerix-36%-16%
595thOrthocell-45%
835thSkin Elements-87%
741 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

05/10/17
$65k Bought
16/12/16
$49k Bought
16/12/16
$49k Other
Total value as at the date of the transaction
Source: Morningstar

Revenue

159th↑ResApp Health$999k
161st↓Peppermint Innovation$908k
162nd↓Orthocell$884k
164th-Skin Elements$1.3m
165th↓Dimerix$825k
239 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer